New preclinical findings highlight Telomir-1’s ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene – often called the body’s natural “cell cycle brake.” These results ...
In aggressive human prostate cancer cell models (PC3 xenografts), Telomir-1 inhibited CDKN2A DNA methylation more effectively than both Rapamycin and chemotherapy. These results complement Telomir’s ...
CDKN2A is one of the body’s most important natural defenses against cancer. Often called the “cell cycle brake,” this gene tells cells when to stop dividing and helps damaged cells self-destruct. In ...
MIAMI, FLORIDA / ACCESS Newswire / September 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results